49 results about "Clinical method" patented technology

A minimally invasive, implantable heart sound and ECG monitor and associated method for deriving blood pressure from heart sound data. The device is equipped with an acoustical sensor for detecting first and second heart sounds which are sampled and stored during sensing windows following R-wave and T-wave detections, respectively. ECG and heart sound data are stored in a continuous, looping memory, and segments of data are stored in long-term memory upon an automatic or manual data storage triggering event. Estimated blood pressure is calculated based on custom spectral analysis and processing of the first and second heart sounds. A calibration method includes measuring a patient's blood pressure using a standard clinical method and performing regression analysis on multiple spectral variables to identify a set of best fit weighted equations for predicting blood pressure. Concurrent ECG and estimated blood pressure may be displayed for review by a physician.

The invention relates to a clinical method and a clinical system for a patient to acquire right to know medical treatment, and belongs to the technical field of information. The system comprises a patient terminal, a platform server, a hospital information system (HIS) interface server, a database server, a doctor work station and a network, and is characterized in that: the patient terminal, the platform server, the HIS interface server, the database server and the doctor work station are connected with one another through the network; and the HIS interface server is connected with an HIS through the network and acquires diagnosis and treatment data. The patient logs in the platform server through the patient terminal, and the platform server verifies the identity of the patient, acquires data from the database server and the HIS interface server and sends the data to the patient terminal. Multiple kinds of related information is provided for the patient, the problem of unequal doctor and patient information is solved, the patient acquires the right to know the medical treatment, and doctor and patient conflicts are furthest reduced.

Methods of inducing a cancer-specific immune response are disclosed through administration of an immune stimulant in the context of tumor cell death induction. Currently used clinical methods of inducing localized tumor cell death are modified to optimize immune response induction. One embodiment of the invention discloses pharmaceutical compositions and kits for modifying the palliative procedure of transarterial chemoembolization so as to promote uptake and presentation of tumor antigens in an immunostimulatory microenvironment, thereby allowing for induction of T cell, B cell and NK responses, which control not only local, but also systemic tumor growth and metastasis.

The present invention is a minimally invasive clinical method for closing hernias and other abnormal openings existing within the body; and is a unique alternative to conventional surgery and routine surgical techniques for correcting such medical defects. The clinical applications for the present methodology can be used for the in-vivo closure of small sized lumens and voids which naturally occur and exist internally within the soft connective tissue and organs of the living human body; can be employed to advantage for the closure of hernias generally; and is focused upon the closure of umbilical hernias specifically.

A method for screening newborns using electrospray tandem mass spectrometry. The method improves the current protocols that use tandem mass spectrometry by assuring accurate and consistent results at the clinical level through enhanced quality controls and quality assurance protocols as applied to the scan profiling and sample preparation of blood spots from newborns. Specific additives are used in precise concentrations of internal standards, employing detailed controls adapted to distinguish twenty metabolites, which are scanned and vigorously compared to known spectra results. Revealing peaks, metabolite concentration, and scan intensities in the quality assurance steps are then compared to a range of thresholds to determine whether or not the sample is contaminated, drug-ridden, diagnosable, or unacceptable. All spectra results and quality assurance flags are organized in spreadsheet form and exported to a database where values are compiled and stored for daily output results and trend analysis. The method provides for high-throughput and quality results, having a consistent predictability for genetically testing newborns efficiently and accurately.

Provided is a multiple birth prognostic tool that is used to analyze data in order to predict a multiple birth event in a female human patient undergoing an infertility treatment. The MBP prognostic tool may also be used to enhance the accuracy of diagnostic or prognostic tests that predict embryo viability. The MBP prognostic tool of the present invention may be clinic specific or it may be modified to be used in a multi-clinic approach.

The present invention relates to diagnostic, prognostic and clinical methods of distinguishing high-risk IPMN from more benign IPMN as well as high-grade PanIN and PDAC from low-grade PanIN with moderate sensitivity and very high specificity using Das-1 and related antibodies.

The invention relates to a test device, which has a pretreatment part covered by a cover (2) having a hole (3) and connected by a hinge (A). The pretreatment part is mounted on the same base (1) as a test strip (not shown). In the lid (2) and the lid of the base are devices (7, 8 and 9) for supporting, fastening and fixing the pretreatment layers, forming excess liquid collection chambers (6), and controlling the flow of sample solutions and diluents. The test device is used in field tests and clinical methods, especially in emergency situations where fast results are required (Fig. 8).

A method of measuring a metabolic activity (MA) of a cell is provided. The method comprising independently measuring in an extracellular environment of the cell, time-dependent acidification profiles due to secretion of:

(i) non-volatile soluble metabolic products;

(ii) non-volatile soluble metabolic products and volatile soluble metabolic products; and

(iii) volatile soluble metabolic products;

wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell. Also provided are clinical methods which make use of the assay.

The invention discloses application of lncRNA combination to preparation of a product for predicting renal clear cell carcinoma prognosis and molecular targeted medicine treatment sensitivity. The lncRNA or the lncRNA combination serving as a detection target point is applied to preparation of the product for predicting renal clear cell carcinoma prognosis and molecular targeted medicine treatmentsensitivity, and the lncRNA or the lncRNA combination is selected from any one or more of SEQ ID NO.1 to SEQ ID NO.4. A new clinical method is provided for evaluating prognosis of patients sufferingfrom renal clear cell carcinoma, new reference advice is provided for auxiliary treatment after operation of the renal clear cell carcinoma, and important clinical significance and popularization andapplication prospect in the aspects of timely taking effective clinical measures, formulating an individualized diagnosis and treatment scheme and finally increasing the survival rate of the patientssuffering from the renal clear cell carcinoma are achieved.

The CellTracks® System provides a system to enumerate CTC's in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies CTC's. The absolute number of CTC's detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. Pre-clinical studies of circulating tumor cells (CTC's) have been limited by the inability to repetitively monitor CTC's in animal models. The present invention provides a method to enumerate CTC's in blood samples obtained from living mice, using a protocol similar to an in vitro diagnostic system for quantifying CTC's in patients. Accordingly, this technology can be adapted for serial monitoring of CTC's in mouse xenograft tumor models of human breast cancer.

The present invention provides highly useful clinical methods for treating skin disorders, particularly intractable skin disorders. Specifically, the methods comprise injecting/subcutaneously introducing a 10 μg to 10 mg dose of a polynucleotide, such as a DNA, oligonucleotide, RNA, siRNA, and antisense, around a lesion associated with a skin disorder, such as a wound, cutaneous ulcer, or psoriasis, using a needleless syringe that injects a pharmaceutical liquid by using gas pressure or the elastic force of an elastic member to drive a piston.

Disclosed are thin inorganic membranes having a defined topography that includes pores having a defined diameter of nanometer and sub-nanometer diameter. The thin membranes are resistant to protein denaturing agents, and may be employed in analytical and clinical methods for identifying single amino acid residues within the sequence of a protein, and the pores are other than MspA pores. Methods for making a thin inorganic membrane with nanopore and sub-nanopore topography and conical cone structure are also disclosed. The thin inorganic membrane may be comprised of any denaturant-resistant materials, such as silicon nitride. A method for manufacturing the thin inorganic membrane with nanopores is also provided, and provides a thin surface with a defined conical topography, the nanopores being provided on the membrane surface with an electron beam sputtering technique.

The invention is intended to adapt an already established clinical procedure for the treatment of multiple sclerosis (MS)—the use of beta interferon—to treat chronic human spinal cord injury. The present invention relates to the prevention of chronic inflammation and demyelination following spinal cord injury.

Available evidence indicates that tumor cells exhibit consistent abnormalities in Calcium influx and intracellular storage of sequestered Calcium when compared to normal cells. The present invention provides clinical methods by which such differences are exploited to induce Apoptosis selectively in tumor cells while sparing normal cells. These methods are based upon employing drugs that, acting alone or in synergistic combinations, produce an increase in intracellular Calcium loading such that either or both of two major Apoptotic pathways are triggered to produce selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that Calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation.

The invention relates to the detection or prediction of metastases of head and neck squamous cell carcinoma (HNSCC) with the use of gene expression profiles. A gene signature has been identified which is able to detect or predict the occurrence of these metastases better than current clinical methods. Part of the invention are micro-arrays comprising this signature and methods for performing the detection and/or prediction.

The invention provides a novel and highly-sensitive detection method for human cytomegalovirus (HCMV). The method represents a nested quantitative PCR (polymerase chain reaction) technique which can detect both free HCMV and HCMV that infects a cell, and is characterized in that nucleic acid is extracted from human peripheral blood mononuclear cells (PBMCs), and a first round of PCR amplification is carried out through specific outer upstream and downstream primers; with the products of the first round of PCR amplification serving as a template, a second round of quantitative PCR amplification is carried out through specific inner upstream and downstream primers. By adopting the detection method provided by the invention, the HCMV detection sensitivity can reach 8 copies per microliter. Compared with the ELISA (enzyme-linked immunoabsorbent assay) method, compared with the ELISA method, the method adopting the PCR method for the detection of the latent HCMV infection has the advantages of rapidness, simplicity, high sensitivity, strong specificity, good stability and the like, and is a clinical method for early detection and diagnosis.

The invention provides a preparation method of teeth whitening liquid based on atmospheric pressure low-pressure plasma, aiming at overcoming the shortcoming that an existing clinical method of whitening teeth by gel containing high-concentration hydrogen peroxide has low efficiency and irritates the teeth and soft tissues. The preparation method is characterized in that the preparation method depends on physical equipment, namely the low-temperature plasma, a certain amount of gas is introduced into a low-temperature plasma generation device, and the low-temperature plasma generation device is electrically driven; a certain amount of water is taken, and the device is placed above the liquid surface of the water solution (attached drawing 2) or below the liquid surface of the water solution (attached drawing 1) by a certain distance so as to stimulate the interaction between the plasma and the water; and after the plasma and the water interact for a certain time, the water becomes the teeth whitening liquid based on the atmospheric pressure low-pressure plasma. The teeth whitening liquid prepared by the method is non-toxic, non-irritant and free of peculiar smell and residues and has a very strong teeth whitening effect.

This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins.

The invention relates to the technical field of medical instruments. In the widely-applied clinical method for cutting the tracheal cannula of a patient with a fixed trachea, a cotton rope, a cotton strip or gauze is knotted on tracheal cannula fixing hole(s) at one end or two ends for fixing the tracheal cannula on the neck part. The invention aims to provide a tracheal cannula fixing article used after tracheotomy, which can be replaced quickly without knotting. The fixing article consists of a hollow tracheal cannula fixing rope (2) of which the pipe walls at the two ends are provided with lock catches, and two self-locking devices (3). When the tracheal cannula fixing article is in use, residual parts at the two ends of the tracheal cannula fixing rope are cut off in comparison to the practical neck circumference, the self-locking devices pass through the tracheal cannula fixing hole(s), self-locking ends are enclosed, and the enclosed self-locking ends are inserted into the two ends of the hollow tracheal cannula fixing rope and is buckled with the lock catches on the pipe walls. By adopting the tracheal cannula fixing article, the accidental falling probability of the tracheal cannula and the neck skin or wound damage and infection risks of the patient are lowered, and the pain of the patient and the workload of medical personnel are lowered.

An improved understanding and method for the clinical adjuvant and immunomodulatory use of dsRNAs and ply-ICLC in particular, alone or in conjunction with other drugs and various vaccines designed to prevent or treat various microbial, viral, neoplastic, autoimmune diseases, and or degenerative diseases.